THERAPY DOSSIER · th-afad40d400a3

miR-129-5p mimic (with Lipofectamine 2000)

Other · miR-129-5p mimic (with Lipofectamine 2000); microRNA oligonucleotide.

Evidence & regulatory context

Mechanism: miR-129-5p mimic (with Lipofectamine 2000); microRNA oligonucleotide.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31680116 ↗2019Reported benefit

Protective Effects of MiR-129-5p on Acute Spinal Cord Injury Rats.

RatSpinal cord injuryContusionSprague-DawleyMalen = 36 rats, n = 9 per group across 4 groupsIntrathecal injection into the vertebral canal100 nmol per injectionAfter injury, given under anaesthesia following spinal cord surgery

Model: Acute spinal cord contusion at T10 after laminectomy, modified Allen weight drop apparatus (40 g.cm)

miR-129-5p expression fell by approximately 40 per cent at 12 h after injury and remained reduced to 14 days. Intrathecal miR-129-5p mimic raised BBB scores from day 1 through day 14 versus negative control mimic, reduced tissue loss, damaged cells and TUNEL-positive neurons, and lowered calpain1,…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…